Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic
Best Pharmaceutical Stocks to Buy Now (2025)
Top pharmaceutical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best pharmaceutical stocks to buy now. Learn More.

Industry: Drug Manufacturers - Spec...
B
Pharmaceutical is Zen Rated B and is the 49th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
PAHC
PHIBRO ANIMAL HEALTH CORP
$1.26B40,533,60844.43%55.57%Net Buying
CPIX
CUMBERLAND PHARMACEUTICALS INC
$49.97M14,961,13728.61%55.80%Net BuyingNet Buying
AMRX
AMNEAL PHARMACEUTICALS INC
$2.63B313,419,59926.47%73.53%Net SellingNet Selling
INDV
INDIVIOR PLC
$1.92B124,769,53373.15%0.00%
KMDA
KAMADA LTD
$461.19M57,505,0318.98%0.00%
ANIP
ANI PHARMACEUTICALS INC
$1.43B21,661,93529.20%70.80%Net SellingNet Selling
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$18.96B1,146,959,85562.02%0.79%Net SellingNet Selling
PCRX
PACIRA BIOSCIENCES INC
$1.10B46,304,66768.64%31.36%Net SellingNet Selling
COLL
COLLEGIUM PHARMACEUTICAL INC
$1.06B32,142,19256.76%43.24%Net SellingNet Buying
HCM
HUTCHMED (CHINA) LTD
$2.78B871,601,0950.75%0.00%
PRGO
PERRIGO CO PLC
$3.75B137,477,30662.20%37.80%Net BuyingNet Buying
ETON
ETON PHARMACEUTICALS INC
$417.28M26,817,53552.66%32.38%Net BuyingNet Selling
SUPN
SUPERNUS PHARMACEUTICALS INC
$1.86B55,989,62346.12%53.88%Net Selling
PBH
PRESTIGE CONSUMER HEALTHCARE INC
$3.83B49,414,70768.93%31.07%Net SellingNet Selling
EBS
EMERGENT BIOSOLUTIONS INC
$397.86M54,277,82741.97%58.03%Net SellingNet Buying
ELAN
ELANCO ANIMAL HEALTH INC
$7.47B496,646,50490.57%9.43%Net SellingNet Selling
AVDL
AVADEL PHARMACEUTICALS PLC
$945.14M96,738,93580.36%13.61%Net Buying
AYTU
AYTU BIOPHARMA INC
$14.13M6,170,2465.99%94.01%Net BuyingNet Buying
BGM
BGM GROUP LTD
$69.81M7,226,4801.30%0.00%
DERM
JOURNEY MEDICAL CORP
$168.20M23,295,76921.81%35.74%Net SellingNet Selling
ALVO
ALVOTECH
$2.63B301,805,6775.51%0.00%
BHC
BAUSCH HEALTH COMPANIES INC
$2.45B369,550,08665.97%32.83%Net BuyingNet Buying
HLN
HALEON PLC
$45.92B9,083,725,9196.41%0.00%
VTRS
VIATRIS INC
$10.86B1,173,681,96481.63%18.14%Net SellingNet Buying
ALKS
ALKERMES PLC
$5.02B164,901,28593.22%6.78%Net SellingNet Selling
NBIX
NEUROCRINE BIOSCIENCES INC
$13.35B98,965,82070.23%29.77%Net SellingNet Selling
TKNO
ALPHA TEKNOVA INC
$277.36M53,440,81011.45%64.16%Net BuyingNet Selling
AMPH
AMPHASTAR PHARMACEUTICALS INC
$1.05B47,139,08548.67%51.33%Net BuyingNet Buying
ZTS
ZOETIS INC
$70.70B445,208,05392.59%5.79%Net SellingNet Selling
SIGA
SIGA TECHNOLOGIES INC
$492.94M71,441,08336.08%63.92%Net SellingNet Selling
IRWD
IRONWOOD PHARMACEUTICALS INC
$125.57M161,819,84870.41%29.59%Net SellingNet Selling
LNTH
LANTHEUS HOLDINGS INC
$5.80B69,185,83656.65%43.35%Net SellingNet Selling
UPC
UNIVERSE PHARMACEUTICALS INC
$2.12M563,3380.05%0.00%
DVAX
DYNAVAX TECHNOLOGIES CORP
$1.31B120,080,65065.36%34.64%Net Selling
QNTM
QUANTUM BIOPHARMA LTD
$51.29M2,711,0852.58%0.00%
RDY
DR REDDYS LABORATORIES LTD
$12.24B834,455,36513.12%0.00%
CRON
CRONOS GROUP INC
$809.38M385,419,02111.46%48.72%Net SellingNet Selling
OGI
ORGANIGRAM GLOBAL INC
$196.74M133,835,9634.61%0.00%
ORGO
ORGANOGENESIS HOLDINGS INC
$558.16M126,853,5366.26%93.74%Net SellingNet Buying
EOLS
EVOLUS INC
$627.35M64,475,58975.46%24.54%Net SellingNet Selling
RGC
REGENCELL BIOSCIENCE HOLDINGS LTD
$8.19B494,488,9080.00%0.00%
TAK
TAKEDA PHARMACEUTICAL CO LTD
$46.71B1,573,649,6464.51%0.00%
HROW
HARROW INC
$1.15B36,699,55328.43%71.57%Net SellingNet Selling
RMTI
ROCKWELL MEDICAL INC
$44.09M34,174,68716.15%83.85%Net SellingNet Selling
EVO
EVOTEC SE
$1.48B177,553,4565.12%0.00%
SBFM
SUNSHINE BIOPHARMA INC
$7.27M4,555,9451.74%87.90%
ACB
AURORA CANNABIS INC
$263.74M56,234,23113.99%0.00%
KALA
KALA BIO INC
$44.52M6,452,3987.60%92.40%Net BuyingNet Selling
ASRT
ASSERTIO HOLDINGS INC
$68.00M95,780,74126.52%21.34%Net SellingNet Selling
SXTC
CHINA SXT PHARMACEUTICALS INC
$6.68M3,906,4710.14%0.00%
BIOA
BIOAGE LABS INC
$167.78M35,850,03756.57%24.78%Net Buying
LFCR
LIFECORE BIOMEDICAL INC
$325.08M37,025,33149.07%50.93%Net BuyingNet Selling
CRDL
CARDIOL THERAPEUTICS INC
$113.17M82,608,9929.33%0.00%
ESPR
ESPERION THERAPEUTICS INC
$245.77M198,199,46257.14%20.68%Net SellingNet Selling
CGC
CANOPY GROWTH CORP
$220.38M185,192,2107.47%58.10%Net SellingNet Selling
SHPH
SHUTTLE PHARMACEUTICALS HOLDINGS INC
$1.87M439,3722.31%97.69%
TLRY
TILRAY BRANDS INC
$641.14M1,006,495,9269.14%1.85%Net BuyingNet Buying
AQST
AQUESTIVE THERAPEUTICS INC
$400.29M99,327,92844.55%7.79%Net SellingNet Selling
YCBD
CBDMD INC
$8.28M8,908,4060.90%99.10%
RDHL
REDHILL BIOPHARMA LTD
$0.0012,899,831,0000.00%0.00%
IXHL
INCANNEX HEALTHCARE INC
$6.62M29,433,7981.71%15.45%
GELS
GELTEQ LTD
$17.65M9,438,0751.11%0.00%
INCR
INTERCURE LTD
$75.46M47,162,7135.27%0.00%
CPHI
CHINA PHARMA HOLDINGS INC
$6.00M3,262,0020.64%99.36%
FLGC
FLORA GROWTH CORP
$15.82M22,568,6532.41%41.74%Net Buying
AKAN
AKANDA CORP
$2.89M2,047,3320.56%0.00%
DRRX
DURECT CORP
$19.77M31,042,5818.62%91.38%
EVOK
EVOKE PHARMA INC
$9.12M1,492,8582.02%97.98%Net Buying
IMCC
IM CANNABIS CORP
$10.61M3,085,4523.87%0.00%
BFRI
BIOFRONTERA INC
$8.01M9,446,19715.67%5.80%
PRFX
PAINREFORM LTD
$2.06M1,471,4120.05%0.00%
APUS
APIMEDS PHARMACEUTICALS US INC
$20.95M11,575,9830.00%62.98%Net BuyingNet Buying
TXMD
THERAPEUTICSMD INC
$13.89M11,574,3623.66%96.34%Net BuyingNet Buying
TLPH
TALPHERA INC
$10.46M20,503,46311.45%88.55%Net BuyingNet Selling
CTOR
CITIUS ONCOLOGY INC
$232.55M71,552,4020.15%96.54%
SCYX
SCYNEXIS INC
$27.31M39,020,27429.75%23.08%Net Buying
SNOA
SONOMA PHARMACEUTICALS INC
$6.47M1,642,7650.86%99.14%

Pharmaceutical Stocks FAQ

What are the best pharmaceutical stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

1. Phibro Animal Health (NASDAQ:PAHC)


Phibro Animal Health (NASDAQ:PAHC) is the #1 top pharmaceutical stock out of 77 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 45, which is 18 points higher than the pharmaceutical industry average of 27.

PAHC passed 16 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 89.99% over the past year, overperforming other pharmaceutical stocks by 156 percentage points.

Phibro Animal Health has an average 1 year price target of $27.67, a downside of -11.15% from Phibro Animal Health's current stock price of $31.14.

Phibro Animal Health stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Phibro Animal Health, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 33.33% have issued a Strong Sell.

2. Cumberland Pharmaceuticals (NASDAQ:CPIX)


Cumberland Pharmaceuticals (NASDAQ:CPIX) is the #2 top pharmaceutical stock out of 77 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Cumberland Pharmaceuticals (NASDAQ:CPIX) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a Due Diligence Score of 23, which is -4 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates CPIX as a "A".

CPIX passed 7 out of 33 due diligence checks and has weak fundamentals. Cumberland Pharmaceuticals has seen its stock return 133.57% over the past year, overperforming other pharmaceutical stocks by 200 percentage points.

3. Amneal Pharmaceuticals (NASDAQ:AMRX)


Amneal Pharmaceuticals (NASDAQ:AMRX) is the #3 top pharmaceutical stock out of 77 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 25, which is -2 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates AMRX as a "A".

AMRX passed 8 out of 33 due diligence checks and has weak fundamentals. Amneal Pharmaceuticals has seen its stock return 18.17% over the past year, overperforming other pharmaceutical stocks by 84 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $11.50, an upside of 37.07% from Amneal Pharmaceuticals's current stock price of $8.39.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the pharmaceutical stocks with highest dividends?

Out of 7 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

1. Viatris (NASDAQ:VTRS)


Viatris (NASDAQ:VTRS) has an annual dividend yield of 3.89%, which is 2 percentage points higher than the pharmaceutical industry average of 1.75%. Viatris's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Viatris's dividend has shown consistent growth over the last 10 years.

Viatris's dividend payout ratio of -15.1% indicates that its high dividend yield might not be sustainable for the long-term.

2. Perrigo Co (NYSE:PRGO)


Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.09%, which is 1 percentage points higher than the pharmaceutical industry average of 1.75%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -85.6% indicates that its dividend yield might not be sustainable for the long-term.

3. Kamada (NASDAQ:KMDA)


Kamada (NASDAQ:KMDA) has an annual dividend yield of 2.49%, which is 1 percentage points higher than the pharmaceutical industry average of 1.75%.

Kamada's dividend payout ratio of 71.4% indicates that its dividend yield is sustainable for the long-term.

Why are pharmaceutical stocks up?

Pharmaceutical stocks were up 0.46% in the last day, and up 1.81% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are up.

What are the most undervalued pharmaceutical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

1. Ironwood Pharmaceuticals (NASDAQ:IRWD)


Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 0, which is -18 points higher than the pharmaceutical industry average of 18. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates IRWD a Valuation Rating of "A".

Ironwood Pharmaceuticals's stock has dropped -87.99% in the past year. It has underperformed other stocks in the pharmaceutical industry by -22 percentage points.

2. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 0, which is -18 points higher than the pharmaceutical industry average of 18. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates BHC a Valuation Rating of "A".

Bausch Health Companies's stock has dropped -9.56% in the past year. It has overperformed other stocks in the pharmaceutical industry by 57 percentage points.

3. Collegium Pharmaceutical (NASDAQ:COLL)


Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 57, which is 39 points higher than the pharmaceutical industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 5.1% in the past year. It has overperformed other stocks in the pharmaceutical industry by 71 percentage points.

Are pharmaceutical stocks a good buy now?

43.59% of pharmaceutical stocks rated by analysts are a strong buy right now. On average, analysts expect pharmaceutical stocks to rise by 38.13% over the next year.

8.62% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 22.41% of pharmaceutical stocks are rated B (Buy), 51.72% are rated C (Hold), 12.07% are rated D (Sell), and 5.17% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - specialty & generic industry?

The average P/E ratio of the drug manufacturers - specialty & generic industry is -28.49x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.